On November 25, 2020 ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer reported the Company will be presenting at the Evercore ISI 3rd Annual HealthCONx Conference (Press release, ESSA, NOV 25, 2020, https://www.prnewswire.com/news-releases/essa-pharma-to-participate-at-evercore-isi-3rd-annual-healthconx-conference-301180096.html [SID1234571759]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. David. R. Parkinson, Chief Executive Officer, will present a corporate overview of the Company’s business. Dr. Parkinson along with ESSA’s Chief Operating Officer, Peter Virsik, and Chief Financial Officer, David S. Wood will be available for one-on-one meetings from December 1 – 3, 2020.

The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com. A replay of the presentations will be available on the Company’s website for 90 days.